Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving Hydroxychloroquine or Favipiravir.
Alosaimi B, Alshanbari HM, Alturaiqy M, AlRawi HZ, Alamri S, Albujaidy A, Bin Sabaan A, Alrashed AA, Alamer A, Alghofaili F, Al-Duraymih K, Alshalani AJ, Alturaiki W.
Alosaimi B, et al. Among authors: alshalani aj.
Pharmaceuticals (Basel). 2022 Nov 24;15(12):1456. doi: 10.3390/ph15121456.
Pharmaceuticals (Basel). 2022.
PMID: 36558907
Free PMC article.